News | December 17, 2013

Sartorius Closes Acquisition Of TAP Biosystems Group plc

Request Information

Sartorius, a leading international laboratory and pharmaceutical equipment provider, successfully completed its acquisition of UK company TAP Biosystems Group plc last Monday.

The cash offer made through Sartorius’ wholly owned subsidiary Sartorius Stedim Biotech valued TAP Biosystems Group plc at approximately €33M and had been approved by TAP Biosystems’ shareholders on November 21, 2013.

The takeover of TAP Biosystems Group plc will enable Sartorius to further extend its bioprocess portfolio in the area of fermentation, especially in the early phases of product and process development. Founded in 1987, the company is headquartered in Royston, UK, generated sales revenue of approximately €26M in 2012/2013 and employs around 160 people worldwide.

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties.

About Sartorius
The Sartorius Group is a leading international laboratory and process technology provider covering the segments of Bioprocess Solutions, Lab Products & Services and Industrial Weighing. In 2012, the technology group earned sales revenue of 845.7 million euros. Founded in 1870, the Goettingen-based company currently employs around 5,500 persons. The major areas of activity of its Bioprocess Solutions segment cover filtration, fluid management, fermentation, cell cultivation and purification, and focus on production processes in the biopharmaceutical industry. The Lab Products & Services segment primarily manufactures laboratory instruments and consumables. Industrial Weighing concentrates on weighing, monitoring and control applications in the manufacturing processes of the food, chemical and pharma sectors. Sartorius has its own production facilities in Europe, Asia and America as well as sales subsidiaries and local commercial agencies in more than 110 countries.

SOURCE: Sartorius Stedim Biotech